Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Julphar
Harvard Business School
McKinsey
Boehringer Ingelheim
Accenture
Citi
QuintilesIMS
AstraZeneca
McKesson

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,110,553

« Back to Dashboard

Which drugs does patent 8,110,553 protect, and when does it expire?

Patent 8,110,553 protects LINZESS and is included in one NDA.

This patent has seventy-four patent family members in twenty-four countries.
Summary for Patent: 8,110,553
Title:Methods and compositions for the treatment of gastrointestinal disorders
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Milne; G. Todd (Brookline, MA), Norman; Thea (Cambridge, MA)
Assignee: Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/788,979
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,110,553

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,110,553

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,304,036 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
7,745,409 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
7,772,188 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
8,080,526 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
7,910,546 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
7,371,727 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
7,704,947 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,110,553

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365174 ➤ Sign Up
Austria 477268 ➤ Sign Up
Australia 2004210161 ➤ Sign Up
Australia 2005222387 ➤ Sign Up
Australia 2009235993 ➤ Sign Up
Brazil PI0407071 ➤ Sign Up
Brazil PI0508558 ➤ Sign Up
Canada 2514507 ➤ Sign Up
Canada 2558050 ➤ Sign Up
China 100589839 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
UBS
US Department of Justice
Express Scripts
Healthtrust
Deloitte
Accenture
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot